ArticleNeuropsychopharmacology reports2026
Combination Versus Monotherapy in Acute Anti-LGI1 Encephalitis: A Real-World Dose Optimization Analysis.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnti-leucine-rich-glioma-inactivated 1 encephalitis (LGI1e) predominantly affects older adults, who frequently present with chronic comorbidities. Given their heightened susceptibility to adverse effects, optimizing immunotherapy is critical for this high-risk population. Therefore, this study compared the efficacy and safety of intravenous immunoglobulin (IVIg), intravenous methylprednisolone (IVMP) at 500 or 1000 mg/day, and combined IVIg with IVMP to define an optimal efficacy-safety balanced regimen for LGI1e.
methodsA total of 131 LGI1e patients were comprehensively analyzed. The efficacy was assessed through the therapeutic response rate, response latency, and the improvement in the Clinical Assessment Scale for Autoimmune Encephalitis (CASE), the modified Rankin Scale (mRS), the Mini-Mental State Examination (MMSE), and faciobrachial dystonic seizure (FBDS), while safety was evaluated by analyzing the incidence and severity of adverse events (AEs).
resultsCompared with IVIg or IVMP monotherapy, the IVIg+IVMP combination achieved higher response rates, shorter latency, and greater improvements in CASE, mRS, and FBDS. While 1000 mg IVMP reduced response latency and FBDS cessation time versus 500 mg, both doses showed comparable response rates. IVMP-containing regimens increased AEs, especially at 1000 mg. Diabetes was the sole independent AE risk factor during acute immunotherapies. Initial regimens had no long-term outcome association, and cognitive impairment persisted as a major disability contributor.
conclusionFor LGI1e patients, combined IVIg and corticosteroid demonstrate superior efficacy to monotherapy as first-line treatment, with a starting IVMP dose of 500 mg (vs. 1000 mg) considered optimal. Furthermore, post-immunotherapy cognitive impairment requires sustained management. These findings necessitate validation in larger randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.